421 results about "Autoantibody" patented technology

The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and / or HAHA) against the drug.

Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest.

The invention provides a human body anti-AQP4 autoantibodies detection material and a preparation method thereof. The preparation method comprises the steps of firstly acquiring M1 and M23 subtype AQP4 overall length target genes, dyeing into an HEK293 cell, and building an HEK293 / pCI-neo-M1-AQP4 cell and an HEK293 / pCI-neo-M23-AQP4 cell expressing M1 and M23 subtype AQP4; extracting an AQP4-cell membrane complex of the cells; finally curing the AQP4-cell membrane complex on a carrier, and obtaining the human body anti-AQP4 autoantibodies detection material. According to the human body anti-AQP4 autoantibodies detection material and the preparation method thereof provided by the invention, the extracted AQP4-cell membrane complex is used as a detection material, so that the intrinsic protein amount causing background coloration can be reduced; compared with a method for using the cell as the detection material for carrying out immunofluorescence detection, the detection sensitivity and the specificity are further increased, a detection result is easier and clear to judge, and the AQP4 autoantibodies of a patient can be simply, conveniently and quickly detected.

The invention relates to a biomarker related to a tumor immunotherapy effect and an application thereof, and discloses a biomarker for predicting the tumor immunotherapy effect, and the biomarker is an autoantibody of a group of tumor-associated antigens. The biomarker can be detected in a sample from a tumor patient to predict the clinical effect of administration of immunotherapy, thereby facilitating the determining of whether the tumor patient can benefit from immunotherapy. The invention also provides an antigen protein combination for detecting the biomarker, a kit containing the antigenprotein combination, and a corresponding detection or diagnosis method.

The present invention relates to unglycosylated isolated and purified recombinant polypeptides comprising a fusion protein able to bind to autoantibodies produced in response to an autoimmune disease associated with an immune reaction to a TSH-receptor (TSHR). Also disclosed are methods of detecting and / or quantifying such autoantibodies using the isolated and purified recombinant polypeptides and respective kits.

There are provided peptides derived from antibodies with reactivity against a GPI linkage epitope and functionally equivalent ligands. These peptides can be used in the therapy and diagnosis of a variety of diseases, all of which are considered to be caused by the inappropriate presence in the body of autoantibodies which are reactive with GPI linkage epitopes. There is also described a mechanism of action of these autoantibodies which compromises the organism, so causing disease, and a method of prevention of disease and detection of the autoantibody.

A method and kit for screening a sample of body fluid for at least one autoantibody to at least one antigen. A source of at least one antigen to the autoantibody is provided. A substrate having immobilized thereto at least one antibody to the antigen is also provided. The antigen source is contacted with the sample of body fluid, so as to obtain a mixture wherein the antigen is allowed to substantially bind with the autoantibody, when the latter is present in the sample of body fluid. The mixture is allowed to flow relative to the substrate so as to allow the mixture to contact the antibody immobilized to the substrate. Labeling means are provided to permit monitoring of binding of the autoanitbody and the antigen present in the mixture, so as to provide an indication of the presence of the autoanitbody in the sample of body fluid.

The present invention relates to a rheumatoid arthritis autoantibody conjugated antigen and applications thereof. The present invention discloses a novel detection antigen of rheumatoid arthritis antibody, wherein particularly the detection antigen can be used as the RA diagnosis and early diagnosis indicator, and is superior to the clinically developed detections of CCP, CRP, IgG-RF, IgM-RF and the like, such that the detection antigen can be used as the valuable reference indicator for clinical early treatment or prevention of RA, and can further be used as the RA pathogenesis development indicator.

The invention relates to a set of a kit for detecting specificity platelet antoantibody by the combination of monoclonal antibody and nano-microspheres. The kit comprises each 3 ml of four types of monoclonal antibody-polystyrene nano-microspheres PBS solution, 6 ml goat-anti-human polyclonal antibody and PBS solution, wherein the four types of the monoclonal antibody-polystyrene nano-microspheres PBS solution are sealed by bovine serum albumin and are respectively connected with a monoclonal antibody SZ-2, a monoclonal antibody SZ-22, a monoclonal antibody SZ-21, a monoclonal antibody 7E3, and the concentration of polystyrene nano-microspheres is 2 mg / ml; the goat-anti-human polyclonal antibody is connected with fluorescein isothiocyanate and with the concentration of the goat-anti-human polyclonal antibody is 15 mug / ml. A detection process of the specificity platelet antoantibody comprises the following steps of: oscillating monoclonal antibody--microspheres and platelet lysis buffer sample for incubation; washing by PBS; adding the goat-anti-human polyclonal antibody connected with the fluorescein isothiocyanate; washing, re-suspending by the PBS; detecting on a flow cytometry to obtain average fluorescence intensity values of the four types of the nano-microspheres respectively; and confirming whether the specificity platelet antoantibody is positive or not according to a ratio of the obtained values to a basic contrast value of that of a healthy person, in order to provide foundation for early diagnosis of ITP. The detection has the advantages of simple process, high sensitivity and good specificity.

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and / or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody- dependent autoimmune diseases.

The present invention relates to an isolated polypeptide useful for immunisation against self-antigens. In particular the invention relates to a self-protein that is capable of raising auto-antibodies when administered in vivo. The invention particularly relates to rendering human cytokines immunogenic in humans. The invention further relates to pharmaceutical compositions comprising such compounds and their use in medicine and to methods for their production.

The invention provides a VEGFR1 antigen polypeptide, which comprises three polypetides: H-DEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLE-OH, H-DLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSI-OH and H-ESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAEL-OH, and application of the antigen polypeptide for detecting the autoantibody of a plasma immune marker VEGFR1. The invention further provides a method of utilizing the VEGFR1 antigen polypeptide to detecting the autoantibody of the plasma immune marker VEGFR1, and a detecting kit containing the VEGFR1 antigen polypeptide.